Abstract

Proteins interact with small molecules to modulate several important cellular functions. Many acute diseases were cured by small molecule binding in the active site of protein either by inhibition or activation. Currently, there are several docking programs to estimate the binding position and the binding orientation of protein–ligand complex. Many scoring functions were developed to estimate the binding strength and predict the effective protein–ligand binding. While the accuracy of current scoring function is limited by several aspects, the solvent effect, entropy effect, and multibody effect are largely ignored in traditional machine learning methods. In this paper, we proposed a new deep neural network-based model named DeepBindRG to predict the binding affinity of protein–ligand complex, which learns all the effects, binding mode, and specificity implicitly by learning protein–ligand interface contact information from a large protein–ligand dataset. During the initial data processing step, the critical interface information was preserved to make sure the input is suitable for the proposed deep learning model. While validating our model on three independent datasets, DeepBindRG achieves root mean squared error (RMSE) value of pKa (−logKd or −logKi) about 1.6–1.8 and R value around 0.5–0.6, which is better than the autodock vina whose RMSE value is about 2.2–2.4 and R value is 0.42–0.57. We also explored the detailed reasons for the performance of DeepBindRG, especially for several failed cases by vina. Furthermore, DeepBindRG performed better for four challenging datasets from DUD.E database with no experimental protein–ligand complexes. The better performance of DeepBindRG than autodock vina in predicting protein–ligand binding affinity indicates that deep learning approach can greatly help with the drug discovery process. We also compare the performance of DeepBindRG with a 4D based deep learning method “pafnucy”, the advantage and limitation of both methods have provided clues for improving the deep learning based protein–ligand prediction model in the future.

Highlights

  • Many complex diseases still prevailed due to lack of effective therapeutic drugs; for instance, many type of cancers, dengue viral disease, Human Immunodeficiency Virus, hypertension, diabetes, and Alzheimer’s disease (Iyengar, 2013; Zahreddine & Borden, 2013)

  • Prediction error was measured with root mean squared error (RMSE), mean absolute error (MAE), mean absolute percentage error (MAPE), and symmetric mean absolute percentage error (sMAPE)

  • We developed a deep learning model “DeepBindRG” for identifying native-like protein–ligand complex

Read more

Summary

Introduction

Many complex diseases still prevailed due to lack of effective therapeutic drugs; for instance, many type of cancers, dengue viral disease, Human Immunodeficiency Virus, hypertension, diabetes, and Alzheimer’s disease (Iyengar, 2013; Zahreddine & Borden, 2013). As the mechanism and targets of these complex diseases gradually being explored, developing effective drugs to block the disease related pathway by protein–ligand interaction becomes possible (Copeland, Pompliano & Meek, 2006). In the post genomics era, some novel therapeutic methods, such as immunotherapy, have tremendously progressed, small molecule drug design is still a dominant way to combat diseases (Anusuya et al, 2018). About 70% approved drugs in the DrugBank database belong to the small molecule category (Wishart et al, 2008). In order to solve the paradox of increasing requirement for new drug and low efficiency of drug development, many researches are focused on developing computational methods to aid the drug discovery (Heifetz et al, 2018)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call